$EGRX on Be prepared for possible Growth
As Eagle Pharma Win Patent Decision for Bendeka, Court issued a favorable patent decision for Bendeka bendamustine hydrochloride injection, or bendamustine HCl , a liquid, low-volume and short-time 10-minute infusion formulation of bendamustine hydrochloride. So with that 
EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy and safety of the medicament, EGRX is showing a good and healthy growth at stock market.
EGRX shares rose 23% to $63.25 in premarket trading. With ongoing evaluation of the efficacy and safety of the medicament, EGRX is showing a good and healthy growth at stock market. 
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.